Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Average Price Target from Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $4.50.

SGMO has been the subject of a number of recent research reports. Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Wall Street Zen cut shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Finally, Barclays lowered their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th.

Sangamo Therapeutics Trading Down 1.5%

Shares of NASDAQ:SGMO traded down $0.01 during trading on Friday, reaching $0.46. The company had a trading volume of 2,638,995 shares, compared to its average volume of 8,776,747. The company has a fifty day moving average of $0.65 and a two-hundred day moving average of $1.18. The stock has a market capitalization of $106.79 million, a P/E ratio of -0.61 and a beta of 1.46. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $6.44 million during the quarter, compared to the consensus estimate of $7.90 million. As a group, equities research analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SGMO. Wealth Management Associates Inc. grew its stake in shares of Sangamo Therapeutics by 213.7% in the first quarter. Wealth Management Associates Inc. now owns 228,400 shares of the biopharmaceutical company's stock worth $150,000 after purchasing an additional 155,600 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Sangamo Therapeutics by 74.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company's stock valued at $851,000 after buying an additional 555,323 shares during the period. Caption Management LLC bought a new position in shares of Sangamo Therapeutics during the first quarter valued at approximately $37,000. OMERS ADMINISTRATION Corp raised its holdings in shares of Sangamo Therapeutics by 93.7% during the first quarter. OMERS ADMINISTRATION Corp now owns 207,800 shares of the biopharmaceutical company's stock valued at $136,000 after acquiring an additional 100,500 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in Sangamo Therapeutics by 82.8% in the first quarter. Invesco Ltd. now owns 483,894 shares of the biopharmaceutical company's stock worth $317,000 after acquiring an additional 219,253 shares during the period. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.